Abstracts tagged "genomics and myositis"

Abstract Number: 2953 • 2014 ACR/ARHP Annual Meeting
International Immunochip Study in the Idiopathic Inflammatory Myopathies Identifies Novel Susceptibility Loci and Confirms HLA As Strongest Genetic Risk Factor
Simon Rothwell¹, Robert G. Cooper², Ingrid E. Lundberg³, Frederick W. Miller⁴, Peter K. Gregersen⁵, Jiri Vencovsky⁶, Katalin Danko⁷, Lucy R Wedderburn⁸, Vidya Limaye⁹, Albert Selva O'Callaghan¹⁰, Michael G. Hanna¹¹, Pedro Machado¹¹, Lauren M. Pachman¹², Ann M. Reed¹³, Lisa G. Rider⁴, Joanna Cobb¹, Hazel Platt¹⁴, Øyvind Molberg¹⁵, Olivier Benveniste¹⁶, Pernille Mathiesen¹⁷, Timothy Radstake¹⁸, Andrea Doria¹⁹, Jan De Bleecker²⁰, Boel De Paepe²¹, Britta Maurer²², William E. Ollier¹⁴, Leonid Padyukov³, Terrance P. O'Hanlon⁴, Annette Lee²³, Hector Chinoy¹ and Janine Lamb¹⁴, ¹Centre for Genetics and Genomics, Arthritis Research UK, University of Manchester, Manchester, United Kingdom, ²MRC/ARUK Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ³Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵The Feinstein Institute for Medical Research, Manhasset, NY, ⁶Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁷University of Debrecen, University of Debrecen, Debrecan, Hungary, ⁸Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁹Royal Adelaide Hospital, Adelaide, Australia, ¹⁰Vall d'Hebron General Hospital, Barcelona, Spain, ¹¹MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom, ¹²Cure JM Myositis Center, Ann & Robert H. Lurie Children's Hospital of Chicago Research Center, Chicago, IL, ¹³Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Centre for Integrated Genomic Medical Research, University of Manchester, Manchester, United Kingdom, ¹⁵Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ¹⁶Internal Medecine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France, ¹⁷Paediatric Department, Holbaek University Hospital, Holbaek, Denmark, ¹⁸University Medical Center Utrecht, Utrecht, Netherlands, ¹⁹Department of Medicine - DIMED, University of Padova, Padova, Italy, ²⁰University of Ghent, Ghent, Belgium, ²¹Neuromuscular Reference Center, University of Ghent, Ghent, Belgium, ²²Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²³Genomics & Human Genetics, Feinstein Institute Med Rsch, Manhasset, NY
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare autoimmune diseases characterised by muscle weakness and extramuscular manifestations such as skin rashes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].